share_log

Truist Securities Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $24

Truist Securities Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $24

Truist Securities维持对Catalyst Pharmicals的买入评级
Benzinga ·  2023/06/21 12:56

Truist Securities analyst Joon Lee maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and raises the price target from $22 to $24.

Truist Securities分析师Joon Lee维持Catalyst Pharmicals(纳斯达克股票代码:CPRX)的买入,并将目标股价从22美元上调至24美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发